Dovato (Dolutegravir/Lamivudine) Side Effects: What to Expect and When to Call Your Doctor

Dovato (dolutegravir/lamivudine) is considered one of the better-tolerated HIV treatments available. Clinical trials showed that most people taking Dovato experienced few or no side effects significant enough to stop treatment. That said, like all medications, Dovato does carry potential side effects — some common and manageable, others rare but serious.

This guide explains what to expect, which side effects need a doctor's attention promptly, and what the Boxed Warning means for patients with hepatitis B co-infection.

Dovato's Boxed Warning: Hepatitis B Co-infection

Dovato carries a Boxed Warning — the FDA's most serious safety notice — specifically for patients co-infected with both HIV and hepatitis B virus (HBV). There are two critical risks:

• Development of lamivudine-resistant HBV: In patients co-infected with HIV and HBV, the lamivudine in Dovato alone is not adequate to fully suppress HBV. Over time, HBV can mutate and become resistant to lamivudine, making it harder to treat.
• Severe HBV exacerbation upon stopping Dovato: If a patient with HBV co-infection stops taking Dovato, their hepatitis B can flare suddenly and severely, including possible liver failure.

All patients should be tested for HBV before starting Dovato. If you have HBV, your provider may recommend a different regimen (such as Biktarvy, which contains tenofovir — a preferred HBV therapy).

Common Side Effects of Dovato

In the GEMINI-1 and GEMINI-2 clinical trials, the most common adverse reactions reported in at least 2% of patients taking Dovato were:

• Headache (3%): The most commonly reported side effect. Usually mild and often improves with time.
• Nausea (2%): Generally mild. Taking Dovato with food may help, though it's not required.
• Diarrhea (2%): Mild gastrointestinal upset that typically improves as the body adjusts.
• Insomnia (2%): Sleep disturbance, related to the dolutegravir component. Some patients find taking Dovato in the morning instead of the evening helps. Discuss with your provider.
• Fatigue: Tiredness, especially early in treatment. This is common with many antiretroviral medications.
• Weight gain: Some patients experience weight gain, which is associated with dolutegravir-containing regimens. However, some weight gain in early HIV treatment also reflects immune recovery. Talk to your doctor about monitoring and management.

Most of these common side effects are mild to moderate and tend to improve after the first few weeks of treatment.

Serious Side Effects: When to Call Your Doctor

While rare, the following serious side effects have been reported with Dovato. Contact your doctor immediately if you experience any of these:

• Allergic/hypersensitivity reaction: Rash, fever, fatigue, muscle or joint aches, blistering skin, mouth sores, or eye redness. These occurred in less than 1% of patients in clinical trials. If you develop a rash, call your doctor right away. Stop Dovato immediately and get emergency care if your rash is accompanied by other symptoms.
• Liver problems: Yellowing of skin or eyes (jaundice), dark urine, abdominal pain, nausea or vomiting, severe fatigue. People with prior hepatitis B or C are at higher risk. Report these symptoms promptly.
• Lactic acidosis: A rare but life-threatening buildup of lactic acid associated with the NRTI class (lamivudine). Symptoms include unusual muscle pain, trouble breathing, stomach pain, nausea, vomiting, and feeling cold.
• Immune reconstitution inflammatory syndrome (IRIS): When HIV treatment is started and the immune system begins to recover, it can trigger inflammation against pre-existing dormant infections (like tuberculosis or CMV). Symptoms depend on the underlying infection but may appear paradoxically as new or worsening illness shortly after starting treatment.
• Neuropsychiatric effects: Depression, anxiety, sleep disturbance, or suicidal thoughts have been reported rarely. Report any significant mood changes to your provider.

Side Effects in Special Populations

Certain groups should be especially attentive to specific Dovato risks:

• Pregnant women or those who may become pregnant: Dolutegravir has been associated with neural tube defects when taken at the time of conception or during the first 12 weeks of pregnancy. A negative pregnancy test is recommended before starting Dovato, and effective contraception is advised.
• People with kidney disease: Dovato is not recommended if creatinine clearance (CrCl) falls below 30 mL/min, as the fixed dose of lamivudine cannot be adjusted. Patients with CrCl 30–49 mL/min should be monitored closely for toxicity.
• People with liver disease: Dovato can be used in mild or moderate liver impairment (Child-Pugh A or B) but is not recommended for severe liver impairment (Child-Pugh C).

The Bottom Line

Dovato is well tolerated by most patients. Common side effects like headache, nausea, and mild insomnia usually improve within the first few weeks. Serious side effects are rare, but it's important to know the warning signs. Always tell your doctor about all medications you take — drug interactions are a key concern with Dovato. See our guide on Dovato drug interactions for more details.